Amicus raises $90 million on back of Amigal

Amicus Therapeutics Inc. (NASDAQ:FOLD) raised $90 million to commercialize its Amigal migalastat to treat Fabry's disease after pricing a follow-on of 13.9 million shares at $6.50 per share on Wednesday.

Amicus intends to meet with European regulators by year end and with FDA in early 2015 to discuss a regulatory path for the compound. ...